BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16184589)

  • 1. Hypereosinophilic syndrome: an update.
    Wilkins HJ; Crane MM; Copeland K; Williams WV
    Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypereosinophilic syndrome and proliferative diseases.
    Ionescu MA; Wang L; Janin A
    Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies for hypereosinophilic syndromes.
    Antoniu SA
    Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practical approach to hypereosinophilia].
    Roufosse F; Cogan E
    Rev Med Brux; 2008 Sep; 29(4):400-8. PubMed ID: 18949995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
    Helbig G; Kyrcz-KrzemieĊ„ S
    Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral mucosa lesions in hypereosinophilic syndrome--an update.
    Ionescu MA; Murata H; Janin A
    Oral Dis; 2008 Mar; 14(2):115-22. PubMed ID: 18194138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypereosinophilic syndrome: case presentation and update.
    Leiferman KM; Gleich GJ
    J Allergy Clin Immunol; 2004 Jan; 113(1):50-8. PubMed ID: 14713907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ; Leiferman KM
    Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW; Ring J; Huss-Marp J; Kahn JE
    J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.
    Lee CH; Mamelak AJ; Vonderheid EC
    Int J Dermatol; 2007 Nov; 46(11):1198-204. PubMed ID: 17988344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
    Kuang FL; Klion AD
    J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The hypereosinophilic syndrome].
    Jegou J; Barete S; Frances C
    Ann Dermatol Venereol; 2003; 130(6-7):664-6. PubMed ID: 13679710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.